Selegiline Hydrochloride is the hydrochloride salt form of selegiline, a levorotatory acetylenic derivative of phenethylamine with antiparkinsonian effect. As a selective monoamine oxidase (MAO) inhibitor, selegiline has the greatest affinity for type B MAO, found mainly in the brain. Selegiline is converted by MAO B to an active moiety, which binds irreversibly at the active site of the enzyme's cofactor FAD (flavin adenine dinucleotide) molecule. This prevents the oxidative deamination of catecholamines and serotonin by MAO B, and leads to an increase in these neurotransmitters' activities resulting in improved motor function. In addition, this agent may inhibit re-uptake of dopamine by the neuron and prolong dopamine activity.

Market Analysis and Insights: Global Selegiline Hydrochloride Market
The global Selegiline Hydrochloride market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Selegiline Hydrochloride Scope and Market Size
The global Selegiline Hydrochloride market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Selegiline Hydrochloride market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Tablet
Capsule

Segment by Application
Parkinson's disease
Depression

The Selegiline Hydrochloride market is analysed and market size information is provided by regions (countries). Segment by Application, the Selegiline Hydrochloride market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Somerset Pharmaceuticals Inc.
Mylan Specialty
Draxis Health Inc.
Deprenyl Research Ltd.
Golden State Medical Supply
Mayne Pharma
Endo Pharmaceuticals
Par Pharmaceutical
Apotex Corp.
A-S Medication Solutions